Study: WHO Should Change PPH Policy That Allows Use of Pfizer’s Misoprostol in Absence of Oxytocin

Drug Industry Daily
A A
World Health Organization (WHO) guidance allowing the use of Pfizer’s misoprostol to prevent postpartum hemorrhage (PPH) when oxytocin is not available is based on flimsy evidence and the global health group should reconsider its policy, according to a new study.

To View This Article:

Login

Subscribe To Drug Industry Daily